Streetbeat News

Products Services

AAPL

IFRA

NVDA

Renowned investor Steve Eisman dismisses fears of a U.S. recession, citing strong market performance driven by AI and infrastructure investments. Eisman highlights the record highs of NVIDIA, Apple, and the iShares U.S. Infrastructure ETF as evidence of economic resilience.

Portfolio Pulse from Benzinga Neuro

June 14, 2024 | 11:03 am

BRK.A

BYDDF

Chinese automakers, led by Warren Buffett-backed BYD, have outsold U.S. brands for the first time, selling 13.4 million vehicles compared to 11.9 million by American brands. This growth is driven by competitive pricing and expansion into emerging markets, despite rising trade tensions and increased tariffs on Chinese EVs.

Portfolio Pulse from Benzinga Neuro

June 14, 2024 | 11:01 am

F

RIVN

TSLA

Elon Musk debunked rumors about the decline of Tesla's supercharger network, stating it is continuing to grow. Tesla plans to invest $500 million in expanding the network this year and has started opening it to rival EV makers. Despite layoffs, Tesla maintains its timeline for opening the network to competitors by Spring 2024.

Portfolio Pulse from Anan Ashraf

June 14, 2024 | 10:47 am

AKRCY

SLB

Schlumberger has finalized a joint venture with Aker Carbon Capture, owning 80% of the new company. This venture aims to promote the adoption of carbon capture technologies in power and industrial sectors globally.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 10:37 am

EGAN

eGain Corporation has been selected by Virginia529 to enhance customer and advisor experience for its Five9 call center and managed services. Virginia529 is the largest 529 plan in the U.S., managing over $100 billion in assets.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 10:33 am

STTK

Shattuck Labs disclosed updated interim data from its Phase 1B clinical trial of SL-172154 in combination with Azacitidine for higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant acute myeloid leukemia (AML) patients. The trial showed a 67% Objective Response Rate (ORR) in HR-MDS patients and a 43% ORR in TP53m AML patients.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 10:16 am

TNXP

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw its stock price rise by 23% in pre-market trading after completing a $4 million public offering. The company plans to use the proceeds for working capital, general corporate purposes, and to prepare a new drug application for its Tonmya product candidate.

Portfolio Pulse from Benzinga Neuro

June 14, 2024 | 10:15 am

ZURA

Zura Bio presented supportive data from a Phase 1 study of its lead candidate, tibulizumab (ZB-106), for the treatment of Sjogren's Syndrome at the Annual European Congress of Rheumatology (EULAR) 2024. The data also support further development of tibulizumab for rheumatoid arthritis (RA).

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 10:09 am

BGNE

BeiGene announced new data from the SEQUOIA study evaluating BRUKINSA plus venetoclax in high-risk first-line CLL/SLL at EHA2024. Preliminary data suggests high efficacy and tolerability.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 10:04 am

TSLA

Tesla's CEO Elon Musk discussed the company's growth potential at the annual shareholder meeting, highlighting opportunities in autonomous transport and humanoid robots. Musk's ambitious market cap targets were met with skepticism by fund manager Jim Chanos. Despite challenges, Tesla's stock saw a slight premarket increase.

Portfolio Pulse from Shanthi Rexaline

June 14, 2024 | 9:35 am